P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer
Nadine Benhamouda(Inserm), Éric Tartour(Centre National de la Recherche Scientifique), Chloé Broudin(Assistance Publique – Hôpitaux de Paris), Patrice Ravel(Inserm), Sébastien Mella(Centre National de la Recherche Scientifique), Joséphine Pineau(Inserm), Milena Hasan(Institut Pasteur), Nathalie Chaput(Institut Gustave Roussy), Valentina Libri(Institut Pasteur), Clémence Granier(Inserm), Antonin Saldmann(Inserm), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Olivier Adotévi(Inserm), Laurence Albigès(Université Paris-Saclay), Ikuan Sam(Inserm), Alain Gey(Inserm), Nicolas Epaillard(Inserm), Virginie Verkarre(Université Paris Cité), Bernd Jabla(Centre National de la Recherche Scientifique), Yann Vano(Délégation Paris 5)
Cited by 2
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
|Annals of Oncology|2017|1.3k
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
|Clinical Cancer Research|2016|1.2k